Home » Stocks » SMMT

Summit Therapeutics PLC (SMMT)

Stock Price: $6.46 USD -0.01 (-0.15%)
Updated Jun 24, 2021 3:37 PM EDT - Market open
Market Cap 641.33M
Revenue (ttm) 728,000
Net Income (ttm) n/a
Shares Out 97.24M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $6.46
Previous Close $6.47
Change ($) -0.01
Change (%) -0.15%
Day's Open 6.69
Day's Range 6.40 - 6.71
Day's Volume 204,151
52-Week Range 3.14 - 12.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconsti...

2 weeks ago - GlobeNewsWire

Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

1 month ago - Zacks Investment Research

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) stock had a big move higher Monday. After reporting earnings and giving a clinical trial update, the stock gained $1.44 a share, a move of almost 27%.

1 month ago - Benzinga

Summit Therapeutics Inc (NASDAQ: SMMT) has selected a new preclinical candidate, SMT026738 (SMT-738), for development against multidrug-resistant infections, specifically carbapenem-resistant Enterobact...

1 month ago - Benzinga

Find out why investors are more excited than ever about these two businesses.

Other stocks mentioned: APPH
1 month ago - The Motley Fool

Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.

1 month ago - GlobeNewsWire

Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.

1 month ago - GlobeNewsWire

Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational ...

1 month ago - GlobeNewsWire

Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time ...

1 month ago - GlobeNewsWire

Summit Therapeutics Inc. (‘Summit' or the ‘Company')

2 months ago - GlobeNewsWire

Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Com...

2 months ago - GlobeNewsWire

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')

7 months ago - GlobeNewsWire

Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')

7 months ago - GlobeNewsWire

Summit Therapeutics Inc. (“Summit” or the “Company”)

7 months ago - GlobeNewsWire

Summit Therapeutics Inc.

8 months ago - GlobeNewsWire

Summit Therapeutics Inc. (‘Summit’, the ‘Company’ or the ‘Group’)

8 months ago - GlobeNewsWire

Summit Therapeutics plc

9 months ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

10 months ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

11 months ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

11 months ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.

1 year ago - Zacks Investment Research

Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’)

1 year ago - GlobeNewsWire

Is (SMMT) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.

1 year ago - Zacks Investment Research

Is (SMMT) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.

1 year ago - Zacks Investment Research

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.

1 year ago - Zacks Investment Research

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.

Other stocks mentioned: DHT, FRO, KALA, SMED
1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for April 7th

Other stocks mentioned: EURN, LIVX, RDHL
1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for March 26th

Other stocks mentioned: GO, NPTN
1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for March 25th

Other stocks mentioned: VIPS, VXRT
1 year ago - Zacks Investment Research

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

1 year ago - GlobeNewsWire

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

TR-1: S tandard form for notification of major holdings

1 year ago - GlobeNewsWire

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

1 year ago - GlobeNewsWire

Summit Therapeutics plc  (‘Summit’ or the ’Company’)

1 year ago - GlobeNewsWire

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

1 year ago - GlobeNewsWire

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva pl... [Read more...]

Industry
Biotechnology
Founded
2003
Stock Exchange
NASDAQ
Ticker Symbol
SMMT
Full Company Profile

Financial Performance

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for SMMT is 4.50, which is a decrease of -30.34% from the latest price.

Price Target
$4.50
(-30.34% downside)